Biotechnology News

Abivax to Participate in Upcoming Fall Investor Conferences PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the...

Abivax participera à plusieurs conférences investisseurs cet automne PARIS, France – le 2 novembre 2026 – 22 h 05 CET – Abivax SA (Euronext Paris : FR0012333284 – ABVX / Nasdaq: ABVX) (« Abivax » ou...

Myriad to participate in UBS Global Healthcare Conference, 2026 Stephens Investment Conference and 38th Annual Piper Sandler Healthcare Conference.

NEEDHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...

Q3 reported revenue of $142.4 million increased 3%Q3 GAAP earnings of $0.08 per diluted share compared to the prior-year period earnings of $0.05 per diluted shareNon-GAAP earnings* of $0.17 per...

NEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...

Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board Mechelen, Belgium; November 2, 2026, 22.01 CET; Lakefront...

Dr. Shahidi beschikt over uitgebreide expertise op het gebied van geneesmiddelenontwikkeling, succesvolle registratieprocedures en baanbrekende operationele ervaring naar de Raad van Bestuur ...

WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...

– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age...